newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

ISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)